Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma

Cancer Immunology, Immunotherapy

Volumn 60, Issue 7, 2011, Pages 985-997

  Anderson Jr , Larry D ^a,b,c   Cook, Danielle R ^a   Yamamoto, Tori N ^a   Berger, Carolina ^a   Maloney, David G ^a   Riddell, Stanley R ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cancer immunology; CT 7; Immunotherapy; MAGE C1; Multiple myeloma

Indexed keywords

EPITOPE; HLA A24 ANTIGEN; MELANOMA ANTIGEN; MELANOMA ANTIGEN C1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; MICE; MICE, TRANSGENIC; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; VACCINATION;

EID: 79959718186     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1009-3     Document Type: Article

References (51)

1. SK Kumar SV Rajkumar A Dispenzieri MQ Lacy SR Hayman FK Buadi SR Zeldenrust D Dingli SJ Russell JA Lust PR Greipp RA Kyle MA Gertz 2008 Improved survival in multiple myeloma and the impact of novel therapies Blood 111 2516 2520 17975015 10.1182/blood-2007-10-116129 1:CAS:528:DC%2BD1cXivFaktrk%3D
2. M Attal JL Harousseau T Facon F Guilhot C Doyen JG Fuzibet M Monconduit C Hulin D Caillot R Bouabdallah L Voillat JJ Sotto B Grosbois R Bataille 2003 Single versus double autologous stem-cell transplantation for multiple myeloma N Engl J Med 349 2495 2502 14695409 10.1056/NEJMoa032290 1:CAS:528: DC%2BD3sXhtVWit7vF (Pubitemid 38010075)
3. JA Child GJ Morgan FE Davies RG Owen SE Bell K Hawkins J Brown MT Drayson PJ Selby 2003 High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N Engl J Med 348 1875 1883 12736280 10.1056/NEJMoa022340 1:CAS:528:DC%2BD3sXjsVChtLo%3D (Pubitemid 36532313)
4. T Facon JY Mary C Hulin L Benboubker M Attal B Pegourie M Renaud JL Harousseau G Guillerm C Chaleteix M Dib L Voillat H Maisonneuve J Troncy V Dorvaux M Monconduit C Martin P Casassus J Jaubert H Jardel C Doyen B Kolb B Anglaret B Grosbois I Yakoub-Agha C Mathiot H Avet-Loiseau 2007 Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial Lancet 370 1209 1218 17920916 10.1016/S0140-6736(07)61537-2 1:CAS:528:DC%2BD2sXhtFehsr%2FN (Pubitemid 47516593)
5. JF San Miguel R Schlag NK Khuageva MA Dimopoulos O Shpilberg M Kropff I Spicka MT Petrucci A Palumbo OS Samoilova A Dmoszynska KM Abdulkadyrov R Schots B Jiang MV Mateos KC Anderson DL Esseltine K Liu A Cakana H van de Velde PG Richardson 2008 Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma N Engl J Med 359 906 917 18753647 10.1056/NEJMoa0801479 1:CAS:528:DC%2BD1cXhtVGms77K
6. WI Bensinger CD Buckner C Anasetti R Clift R Storb T Barnett T Chauncey H Shulman FR Appelbaum 1996 Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome Blood 88 2787 2793 8839877 1:CAS:528:DyaK28XmtFSmtL8%3D (Pubitemid 26327535)
7. B Bruno M Rotta F Patriarca N Mordini B Allione F Carnevale-Schianca L Giaccone R Sorasio P Omede I Baldi S Bringhen M Massaia M Aglietta A Levis A Gallamini R Fanin A Palumbo R Storb G Ciccone M Boccadoro 2007 A comparison of allografting with autografting for newly diagnosed myeloma N Engl J Med 356 1110 1120 17360989 10.1056/NEJMoa065464 1:CAS:528:DC%2BD2sXivVKit7Y%3D (Pubitemid 46425595)
8. HM Lokhorst K Wu LF Verdonck LL Laterveer NW van de Donk MH van Oers JJ Cornelissen AV Schattenberg 2004 The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma Blood 103 4362 4364 14976044 10.1182/blood-2003-11-3862 1:CAS:528:DC%2BD2cXkvVyitbk%3D (Pubitemid 38685385)
9. MV Dhodapkar J Krasovsky K Olson 2002 T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells Proc Natl Acad Sci USA 99 13009 13013 12235374 10.1073/pnas.202491499 1:CAS:528:DC%2BD38XnvFGhtLk%3D
10. M Massaia U Dianzani A Bianchi A Camponi M Boccadoro A Pileri 1988 Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies Clin Exp Immunol 73 214 218 3263229 1:STN:280: DyaL1M%2FivFantw%3D%3D
11. RD Brown B Pope A Murray W Esdale DM Sze J Gibson PJ Ho D Hart D Joshua 2001 Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10 Blood 98 2992 2998 11698282 10.1182/blood.V98.10.2992 1:CAS:528:DC%2BD3MXosFynsbg%3D
12. KM Dhodapkar J Krasovsky B Williamson MV Dhodapkar 2002 Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells J Exp Med 195 125 133 11781371 10.1084/jem.20011097 1:CAS:528:DC%2BD38XjslOjtQ%3D%3D (Pubitemid 34074502)
13. K Noonan W Matsui P Serafini R Carbley G Tan J Khalili M Bonyhadi H Levitsky K Whartenby I Borrello 2005 Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors Cancer Res 65 2026 2034 15753403 10.1158/0008-5472.CAN-04-3337 1:CAS:528:DC%2BD2MXitVOjtL4%3D (Pubitemid 40478633)
14. + T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma Blood 112 3362 3372 18658027 10.1182/blood-2008-04-149393 1:CAS:528:DC%2BD1cXht1Omur3J
15. D Atanackovic J Arfsten Y Cao S Gnjatic F Schnieders K Bartels G Schilling C Faltz C Wolschke J Dierlamm G Ritter T Eiermann DK Hossfeld AR Zander AA Jungbluth LJ Old C Bokemeyer N Kroger 2007 Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation Blood 109 1103 1112 17023585 10.1182/blood-2006-04-014480 1:CAS:528:DC%2BD2sXjtFert7g%3D (Pubitemid 46220657)
16. S Blotta P Tassone RH Prabhala P Tagliaferri D Cervi S Amin J Jakubikova YT Tai K Podar CS Mitsiades A Zullo B Franco KC Anderson NC Munshi 2009 Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance Blood 114 3276 3284 19587378 10.1182/blood-2009-04-219436 1:CAS:528:DC%2BD1MXhtlShtbnK
17. MV Dhodapkar J Krasovsky K Osman MD Geller 2003 Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy J Exp Med 198 1753 1757 14638846 10.1084/jem.20031030 1:CAS:528:DC%2BD3sXps1egurc%3D (Pubitemid 37494167)
18. R Spisek A Kukreja LC Chen P Matthews A Mazumder D Vesole S Jagannath HA Zebroski AJ Simpson G Ritter B Durie J Crowley JD Shaughnessy Jr MJ Scanlan AO Gure B Barlogie MV Dhodapkar 2007 Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy J Exp Med 204 831 840 17389240 10.1084/jem.20062387 1:CAS:528:DC%2BD2sXksFSqurg%3D (Pubitemid 46631612)
19. ME Dudley JC Yang R Sherry MS Hughes R Royal U Kammula PF Robbins J Huang DE Citrin SF Leitman J Wunderlich NP Restifo A Thomasian SG Downey FO Smith J Klapper K Morton C Laurencot DE White SA Rosenberg 2008 Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens J Clin Oncol 26 5233 5239 18809613 10.1200/JCO.2008.16.5449 1:CAS:528:DC%2BD1cXhsVyqsrbO
20. SA Rosenberg ME Dudley 2009 Adoptive cell therapy for the treatment of patients with metastatic melanoma Curr Opin Immunol 21 233 240 19304471 10.1016/j.coi.2009.03.002 1:CAS:528:DC%2BD1MXlsVCgtb8%3D
21. MV Dhodapkar K Osman J Teruya-Feldstein D Filippa CV Hedvat K Iversen D Kolb MD Geller H Hassoun T Kewalramani RL Comenzo K Coplan YT Chen AA Jungbluth 2003 Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease Cancer Immunol 3 9
22. AA Jungbluth YT Chen KJ Busam K Coplan D Kolb K Iversen B Williamson FK Van Landeghem E Stockert LJ Old 2002 CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues Int J Cancer 99 839 845 12115486 10.1002/ijc.10416 1:CAS:528:DC%2BD38XksVajs7c%3D (Pubitemid 34575702)
23. AA Jungbluth S Ely M DiLiberto R Niesvizky B Williamson D Frosina YT Chen N Bhardwaj S Chen-Kiang LJ Old HJ Cho 2005 The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation Blood 106 167 174 15761016 10.1182/blood-2004- 12-4931 1:CAS:528:DC%2BD2MXlvVWjsLc%3D (Pubitemid 40967189)
24. A Curioni-Fontecedro AJ Knights M Tinguely N Nuber C Schneider CW Thomson L von Boehmer W Bossart S Pahlich H Gehring H Moch C Renner A Knuth A Zippelius 2008 MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma Leukemia 22 1646 1648 18323799 10.1038/leu.2008.43 1:CAS:528:DC%2BD1cXpslSnt7o%3D
25. Lendvai N, Gnjatic S, Ritter E, Mangone M, Austin W, Reyner K, Jayabalan D, Niesvizky R, Jagannath S, Bhardwaj N, Chen-Kiang S, Old LJ, Cho HJ (2010) Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. Cancer Immun 10:4
26. + cytotoxic T-cell clones specific for NY-BR-1 Cancer Res 66 6826 6833 16818660 10.1158/0008-5472.CAN-05-3529 1:CAS:528: DC%2BD28XmsValsL0%3D (Pubitemid 44085643)
27. B Thurner C Roder D Dieckmann M Heuer M Kruse A Glaser P Keikavoussi E Kampgen A Bender G Schuler 1999 Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application J Immunol Methods 223 1 15 10037230 10.1016/S0022-1759(98)00208-7 1:CAS:528:DyaK1MXksFKqtw%3D%3D (Pubitemid 29096234)
28. + T-cell clones for immunotherapy from the naive repertoire J Immunol Methods 310 40 52 16469329 10.1016/j.jim.2005.11.023 1:CAS:528:DC%2BD28Xit1Ogsbw%3D (Pubitemid 43375974)
29. + T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients Clin Cancer Res 3 221 226 9815676 1:CAS:528:DyaK2sXhsVOmsbY%3D (Pubitemid 27107298)
30. H Firat F Garcia-Pons S Tourdot S Pascolo A Scardino Z Garcia ML Michel RW Jack G Jung K Kosmatopoulos L Mateo A Suhrbier FA Lemonnier P Langlade-Demoyen 1999 H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies Eur J Immunol 29 3112 3121 10540322 10.1002/(SICI)1521-4141(199910) 29:10<3112::AID-IMMU3112>3.0.CO;2-Q 1:CAS:528:DyaK1MXmslOmsbc%3D (Pubitemid 29484201)
31. M Tinguely B Jenni A Knights B Lopes D Korol V Rousson A Curioni Fontecedro SB Cogliatti AG Bittermann U Schmid C Dommann-Scherrer R Maurer C Renner NM Probst-Hensch H Moch A Knuth A Zippelius 2008 MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome Cancer Sci 99 720 725 18307538 10.1111/j.1349-7006.2008.00738.x 1:CAS:528:DC%2BD1cXlsFKgu7c%3D (Pubitemid 351448075)
32. N van Baren F Brasseur D Godelaine G Hames A Ferrant F Lehmann M Andre C Ravoet C Doyen GC Spagnoli M Bakkus K Thielemans T Boon 1999 Genes encoding tumor-specific antigens are expressed in human myeloma cells Blood 94 1156 1164 10438702 (Pubitemid 29380395)
33. MJ Scanlan AO Gure AA Jungbluth LJ Old YT Chen 2002 Cancer/testis antigens: an expanding family of targets for cancer immunotherapy Immunol Rev 188 22 32 12445278 10.1034/j.1600-065X.2002.18803.x 1:CAS:528: DC%2BD38Xps1Oqsr4%3D (Pubitemid 35398862)
34. J Yuan S Gnjatic H Li S Powel HF Gallardo E Ritter GY Ku AA Jungbluth NH Segal TS Rasalan G Manukian Y Xu RA Roman SL Terzulli M Heywood E Pogoriler G Ritter LJ Old JP Allison JD Wolchok 2008 CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit Proc Natl Acad Sci USA 105 20410 20415 19074257 10.1073/pnas.0810114105 1:CAS:528:DC%2BD1MXhsFWktA%3D%3D
35. RH Prabhala P Neri JE Bae P Tassone MA Shammas CK Allam JF Daley D Chauhan E Blanchard HS Thatte KC Anderson NC Munshi 2006 Dysfunctional T regulatory cells in multiple myeloma Blood 107 301 304 16150935 10.1182/blood-2005-08-3101 1:CAS:528:DC%2BD28XhsVGltg%3D%3D (Pubitemid 43053555)
36. SR Riddell M Elliott DA Lewinsohn MJ Gilbert L Wilson SA Manley SD Lupton RW Overell TC Reynolds L Corey PD Greenberg 1996 T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients Nat Med 2 216 223 8574968 10.1038/nm0296-216 1:CAS:528:DyaK28Xps1yksg%3D%3D (Pubitemid 26057556)
37. C Berger ME Flowers EH Warren SR Riddell 2006 Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation Blood 107 2294 2302 16282341 10.1182/blood-2005-08-3503 1:CAS:528:DC%2BD28XisFOjtL0%3D (Pubitemid 43345547)
38. LM Muul F Candotti 2007 Immune responses to gene-modified T cells Curr Gene Ther 7 361 368 17979682 10.2174/156652307782151489 1:CAS:528: DC%2BD1cXhsVKjug%3D%3D (Pubitemid 47595778)
39. P Mercier-Letondal M Deschamps D Sauce JM Certoux N Milpied B Lioure JY Cahn E Deconinck C Ferrand P Tiberghien E Robinet 2008 Early immune response against retrovirally transduced herpes simplex virus thymidine kinase-expressing gene-modified T cells confused with a T cell-depleted marrow graft: an altered immune response? Hum Gene Ther 19 937 950 18810797 10.1089/hum.2007.156 1:CAS:528:DC%2BD1cXhtFWls7rE
40. R Fontana M Bregni A Cipponi L Raccosta C Rainelli D Maggioni F Lunghi F Ciceri S Mukenge C Doglioni D Colau PG Coulie C Bordignon C Traversari V Russo 2009 Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients Blood 113 1651 1660 19074732 10.1182/blood-2008-07-168666 1:CAS:528:DC%2BD1MXisV2iurk%3D
41. V Russo A Cipponi L Raccosta C Rainelli R Fontana D Maggioni F Lunghi S Mukenge F Ciceri M Bregni C Bordignon C Traversari 2007 Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity J Clin Invest 117 3087 3096 17885685 10.1172/JCI30605 1:CAS:528:DC%2BD2sXhtFCnt7jO (Pubitemid 47529638)
42. JT Snyder IM Belyakov A Dzutsev F Lemonnier JA Berzofsky 2004 Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8(+) T-cell peptide epitope of vaccinia and variola viruses J Virol 78 7052 7060 15194781 10.1128/JVI.78.13.7052-7060.2004 1:CAS:528:DC%2BD2cXltFOisLY%3D (Pubitemid 38781543)
43. MA Alexander-Miller GR Leggatt JA Berzofsky 1996 Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy Proc Natl Acad Sci USA 93 4102 4107 8633023 10.1073/pnas.93.9.4102 1:CAS:528:DyaK28XivVKru7g%3D (Pubitemid 26144250)
44. SA Rosenberg JC Yang DJ Schwartzentruber P Hwu FM Marincola SL Topalian NP Restifo ME Dudley SL Schwarz PJ Spiess JR Wunderlich MR Parkhurst Y Kawakami CA Seipp JH Einhorn DE White 1998 Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Nat Med 4 321 327 9500606 10.1038/nm0398-321 1:CAS:528:DyaK1cXhs1Kju7c%3D (Pubitemid 28144091)
45. D Atanackovic T Luetkens Y Hildebrandt J Arfsten K Bartels C Horn T Stahl Y Cao AR Zander C Bokemeyer N Kroger 2009 Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma Clin Cancer Res 15 1343 1352 19190130 10.1158/1078-0432.CCR-08-0989 1:CAS:528: DC%2BD1MXitVOkt78%3D
46. VC Andrade AL Vettore RS Felix MS Almeida F Carvalho JS Oliveira ML Chauffaille A Andriolo OL Caballero MA Zago GW Colleoni 2008 Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients Cancer Immunol 8 2
47. D Atanackovic Y Hildebrandt A Jadczak T Luetkens S Meyer K Bartels YR Cao AR Zander C Bokemeyer N Kroeger 2008 Expression of cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 Is central to the survival of myeloma cells and their resistance to chemotherapy Blood 112 1256 1257
48. N Nuber A Curioni-Fontecedro C Matter D Soldini JM Tiercy L von Boehmer H Moch R Dummer A Knuth M van den Broek 2010 Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients Proc Natl Acad Sci USA 107 15187 15192 20696919 10.1073/pnas.1002155107 1:CAS:528:DC%2BC3cXhtFSnsLvK
49. + melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor Cancer Res 65 1570 1576 15735047 10.1158/0008-5472.CAN-04-2076 1:CAS:528: DC%2BD2MXhsFKqtbs%3D (Pubitemid 40270187)
50. LD Anderson Jr S Mori S Mann CA Savary CA Mullen 2000 Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease Cancer Res 60 5797 5802 11059776 1:CAS:528:DC%2BD3cXnvVSnt78%3D
51. L Sanchez-Perez T Kottke RM Diaz A Ahmed J Thompson H Chong A Melcher S Holmen G Daniels RG Vile 2005 Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo Cancer Res 65 2009 2017 15753401 10.1158/0008-5472.CAN-04-3216 1:CAS:528:DC%2BD2MXitVOjt7Y%3D (Pubitemid 40478631)